Hope for FSHD: new drug trial aims to rebuild muscle
Disease control
Not yet recruiting
This study tests a drug called apitegromab in 60 adults with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes muscle weakness. Participants will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug can increase muscle volume…
Phase: PHASE2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC